Last reviewed · How we verify
alendronate
At a glance
| Generic name | alendronate |
|---|---|
| Also known as | Fosamax, ALN, MK0217, MK-0217, FOSAMAX® |
| Sponsor | Massachusetts General Hospital |
| Target | Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10 |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
Approved indications
- Glucocorticoid Induced Osteoporosis
- Hypogonadal Osteoporosis in Males
- Osteitis deformans
- Postmenopausal osteoporosis
- Prevention of Glucocorticoid-Induced Osteoporosis
Common side effects
- Abdominal pain
- Musculoskeletal pain
- Nausea
- Dyspepsia
- Constipation
- Diarrhea
- Flatulence
- Headache
- Acid regurgitation
- Esophageal ulcer
- Vomiting
- Dysphagia
Serious adverse events
- Anastomotic ulcer with hemorrhage
Key clinical trials
- A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head (PHASE2)
- Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes (PHASE2)
- Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis (PHASE3)
- Alendronate for Osteonecrosis in Adults With Sickle Cell Disease (PHASE2)
- Bone, Exercise, Alendronate, and Caloric Restriction (PHASE4)
- Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation (PHASE1, PHASE2)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- The Optimal Sequential Therapy After Long Term Denosumab Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |